Peptide-Guided Nanoparticles Degrade Cancer Immune Checkpoint PD-L1 Deep Inside Tumors
iRGD peptide-engineered PROTAC nanoparticles achieved 67% PD-L1 degradation with deep tumor penetration, outperforming conventional immune checkpoint approaches.
Quick Facts
What This Study Found
Cyclic iRGD peptide-engineered PROTAC nanoparticles achieved 67% PD-L1 degradation with enhanced tumor penetration via integrin/neuropilin-1 pathways.
Key Numbers
67.05% PD-L1 degradation at 5 uM over 24 hours; iRGD peptide targets integrin and neuropilin-1; tested in MC38 colon cancer mouse model.
How They Did This
Rational PROTAC design, peptide-nanoparticle engineering, and preclinical tumor penetration and efficacy evaluation.
Why This Research Matters
Degrading PD-L1 rather than blocking it could provide more durable anti-cancer immunity with lower drug doses and fewer side effects.
The Bigger Picture
This converges peptide biology, protein degradation technology, and nanomedicine to create a next-generation cancer immunotherapy platform.
What This Study Doesn't Tell Us
Preclinical study — human tumor penetration, safety, and immune response need clinical validation.
Questions This Raises
- ?How does PD-L1 degradation compare to PD-L1 blockade for immune activation?
- ?Can the iRGD platform deliver other therapeutic payloads?
Trust & Context
- Key Stat:
- 67% degradation PROTAC nanoparticles achieved 67% PD-L1 protein degradation with iRGD-mediated tumor penetration
- Evidence Grade:
- Preclinical drug development study — innovative technology platform but requires clinical translation.
- Study Age:
- Published in 2025 in J Med Chem, reflecting cutting-edge cancer drug delivery technology.
- Original Title:
- Rational Design of PROTAC Degraders and Their Spatiotemporal Controlled Delivery for Enhanced Tumor Penetration and PD-L1 Protein Degradation.
- Published In:
- Journal of medicinal chemistry, 68(21), 22665-22688 (2025)
- Authors:
- Qi, Qianqian(2), Zhang, Zhanyu, Ji, Xiang, Wang, Dun
- Database ID:
- RPEP-13137
Evidence Hierarchy
Frequently Asked Questions
What is a PROTAC?
A molecule that tags unwanted proteins (like PD-L1) for destruction by the cell's own recycling machinery, rather than just blocking them.
How does the iRGD peptide help?
It guides the nanoparticles deep into tumors by binding to receptors that trigger transport across cell layers, overcoming a major drug delivery barrier.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-13137APA
Qi, Qianqian; Zhang, Zhanyu; Ji, Xiang; Wang, Dun. (2025). Rational Design of PROTAC Degraders and Their Spatiotemporal Controlled Delivery for Enhanced Tumor Penetration and PD-L1 Protein Degradation.. Journal of medicinal chemistry, 68(21), 22665-22688. https://doi.org/10.1021/acs.jmedchem.5c01632
MLA
Qi, Qianqian, et al. "Rational Design of PROTAC Degraders and Their Spatiotemporal Controlled Delivery for Enhanced Tumor Penetration and PD-L1 Protein Degradation.." Journal of medicinal chemistry, 2025. https://doi.org/10.1021/acs.jmedchem.5c01632
RethinkPeptides
RethinkPeptides Research Database. "Rational Design of PROTAC Degraders and Their Spatiotemporal..." RPEP-13137. Retrieved from https://rethinkpeptides.com/research/qi-2025-rational-design-of-protac
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.